Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009–2013

Emerging Infectious Diseases

Volumn 22, Issue 1, 2016, Pages 56-64

  Cameron, Ross L ^a   Kavanagh, Kimberley ^b   Pan, Jiafeng ^b   Love, John ^a   Cuschieri, Kate ^c   Robertson, Chris ^b   Ahmed, Syed ^a   Palmer, Timothy ^d   Pollock, Kevin G J ^a  

^a HEALTH PROTECTION SCOTLAND   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c Scottish Human Papillomavirus Reference Laboratory   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; DISEASE SURVEILLANCE; FEMALE; GENOTYPING TECHNIQUE; GEOGRAPHIC DISTRIBUTION; HERD IMMUNITY; HIGH RISK POPULATION; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; SCORING SYSTEM; UTERINE CERVIX CYTOLOGY; VACCINATION; WART VIRUS; YOUNG ADULT; CROSS PROTECTION; IMMUNOLOGY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; PREVENTIVE HEALTH SERVICE; PROCEDURES; SCOTLAND;

ADULT; CROSS PROTECTION; FEMALE; HUMANS; IMMUNITY, HERD; IMMUNIZATION PROGRAMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; SCOTLAND; VACCINATION; YOUNG ADULT;

EID: 84950301776     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2201.150736     Document Type: Article

References (26)

1. Ladner J, Besson MH, Rodrigues M, Audureau E, Saba J. Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009–2013. BMC Public Health. 2014;14:670. http://dx.doi.org/10.1186/1471-2458-14-670
2. Remschmidt C, Fesenfeld M, Kaufmann A, Delere Y. Sexual behavior and factors associated with young age at first intercourse and HPV vaccine uptake among young women in Germany: implications for HPV vaccination policies. BMC Public Health. 2014;14:1248. http://dx.doi.org/10.1186/1471-2458-14-1248
3. Garland SM. The Australian experience with the human papillomavirus vaccine. Clin Ther. 2014;36:17–23. http://dx.doi.org/10.1016/j.clinthera.2013.12.005
4. Sinka K, Kavanagh K, Gordon R, Love J, Potts A, Donaghy M, et al. Achieving high and equitable coverage of adolescent HPV vaccine in Scotland. J Epidemiol Community Health. 2014;68: 57–63. http://dx.doi.org/10.1136/jech-2013-202620
5. Kavanagh K, Pollock KGJ, Potts A, Love J, Cuschieri K, Cubie H, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014;110:2804–11. http://dx.doi.org/10.1038/bjc.2014.198
6. Mesher D, Soldan K, Howell-Jones R, Panwar K, Manyenga P, Jit M, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine. 2013;32:26–32. http://dx.doi.org/10.1016/j.vaccine.2013.10.085
7. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis. 2013;208:385–93. http://dx.doi.org/10.1093/infdis/jit192
8. Pollock KGJ, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer. 2014;111:1824–30. http://dx.doi.org/10.1038/bjc.2014.479
9. Rana MM, Huhtala H, Apter D, Eriksson T, Luostarinen T, Natunen K, et al. Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: cancer registry–based follow-up. Int J Cancer. 2013;132:2833–8. http://dx.doi.org/10.1002/ijc.27971
10. Gertig DM, Brotherton JML, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013;11:227. http://dx.doi.org/10.1186/1741-7015-11-227
11. Drolet M, Bénard È, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programs: a systematic review and meta-analysis. Lancet Infect Dis. 2015 14:565–80. http://dx.doi.org/10.1016/S1473-3099(14)71073-4
12. Tabrizi SN, Brotherton JML, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination program in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014;14:958–66. http://dx.doi.org/10.1016/S1473-3099(14)70841-2
13. Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination program: national surveillance data. BMJ. 2013;346:f2032.
14. National Services Scotland ISD. Scottish Cervical Screening Program statistics 2012–13 [cited 2015 Apr 2]. http://www.isdscotland.org/Health-Topics/Cancer/Cervical-Screening/
15. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol. 2006;44:504–12. http://dx.doi.org/10.1128/JCM.44.2.504-512.2006
16. International Agency for Research on Cancer. Biological agents: a review of human carcinogens. Lyon (France): The Agency; 2012;100(B).
17. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103:1444–51. http://dx.doi.org/10.1093/jnci/djr319
18. Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:781–9. http://dx.doi.org/10.1016/S1473-3099(12)70187-1
19. Safaeian M, Rodriguez AC. Invited commentary: multiple human papillomavirus infections and type replacement— anticipating the future after human papillomavirus vaccination. Am J Epidemiol. 2014;180:1076–81. http://dx.doi.org/10.1093/aje/kwu265
20. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26(Suppl 10):K1–K16.
21. Tota JE, Ramanakumar AV, Villa LL, Richardson H, Burchell AN, Koushik A, et al. Evaluation of human papillomavirus type replacement postvaccination must account for diagnostic artifacts: masking of HPV 52 by HPV 16 in anogenital specimens. Cancer Epidemiol Biomarkers Prev. 2015;24:286–90. http://dx.doi.org/10.1158/1055-9965.EPI-14-0566
22. Osborne SL, Tabrizi SN, Brotherton JML, Cornall AM, Wark JD, Wrede CD, et al. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine. 2015; 33:201–8. http://dx.doi.org/10.1016/j.vaccine.2014.10.045
23. Sinka K, Lacey M, Robertson C, Kavanagh K, Cuschieri K, Nicholson D, et al. Acceptability and response to a postal survey using self-taken samples for HPV vaccine impact monitoring. Sex Transm Infect. 2011;87:548–52. http://dx.doi.org/10.1136/sextrans-2011-050211
24. Mercer CH, Tanton C, Prah P, Erens B, Sonnenberg P, Clifton S, et al. Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet. 2013;382:1781–94. http://dx.doi.org/10.1016/S0140-6736(13)62035-8
25. Potts A, Wallace L, Shaw Primrose L, Nicholson D, Eastwick K, Goldberg D. Genital herpes simplex, genital chlamydia and gonorrhoea infection in Scotland: laboratory diagnoses 2005–2014. Glasgow (Scotland): Health Protection Scotland; 2015.
26. Kavanagh K, Sinka K, Cuschieri K, Love J, Potts A, Pollock K, et al. Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact. BMC Infect Dis. 2013;13:519. http://dx.doi.org/10.1186/1471-2334-13-519